Drugs / Lipiodal
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06806189 | Apr 2025 → Mar 2026 overdue | head and neck cancer | Western University, Canada | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lipiodal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06806189 ↗ |
| Modality | Diagnostic / imaging agent | “safe contrast agent (material injected to enhance x-ray and ct images)” NCT06806189 ↗ |
| Route | Subcutaneous | “approved and indicated for subcutaneous injection in children and adults” NCT06806189 ↗ |